Conference Coverage
Conference Coverage
Finerenone’s heart benefits hold up in T2D patients without CVD
In the FIDELIO-DKD trial, cardiovascular benefits from a nonsteroidal mineralocorticoid antagonist held, regardless of CVD history, in T2D...
Conference Coverage
First SGLT1/2 inhibitor shows ‘spectacular’ phase 3 safety and efficacy in T2D
A pair of pivotal trials showed safety and efficacy for sotagliflozin for patients with type 2 diabetes, including novel benefits from an SGLT...
Conference Coverage
Don’t miss cardiovascular risk factors in transgender patients
Transgender patients seeking gender affirming hormone therapy showed an increased risk of cardiovascular disease at baseline
Conference Coverage
Novel drug slows progression of diabetic kidney disease
Finerenone, a selective, nonsteroidal mineralocorticoid receptor antagonist, significantly reduced both renal and cardiovascular events, with good...
Conference Coverage
Experts tout immediate quadruple therapy for HFrEF patients
Recent evidence cemented four drug classes as foundational pillars of HFrEF treatment. The answer to how to start them: immediately and all at...
Conference Coverage
‘Modest’ benefit for post-MI T2D glucose monitoring
Equivocal results were seen with regard to the best method to monitor blood glucose after myocardial infarction.
Conference Coverage
Diabetic neuropathic pain linked to brain bioenergic anomalies
Changes in mitochondrial activity in pain-processing areas of the brain may help explain why some persons with diabetes experience painful...
News
Substance in tears could be used for diabetes monitoring
Measuring glycoalbumin in tears could someday be a way for patients with diabetes to monitor their glucose levels noninvasively.
Conference Coverage
T2D treatments create tension between glycemic and cardiovascular goals
Recent society guidelines clash on whether metformin or newer drug classes should start first when treating patients with type 2 diabetes.
Conference Coverage
Empagliflozin cut PA pressures in heart failure patients
The drops in pulmonary artery pressure were modest but large enough to be clinically meaningful, they appeared quickly, and increased over time....